Payment overview · 2025
General Payments
$346.39
15 reported records · 14 companies
Healthcare provider profile · identity verified
Tarra Marsh Boyd, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MINT HILL, NC · NPI 1649762451
Verified facts
What the public records show
CMS Open Payments records show Tarra Marsh Boyd, FNP received $346.39 in general payments during 2025 across 15 reported records.
Viatris Specialty LLC accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $79.17 | 22.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.07 | 9.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.23 | 7.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.44 | 6.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.20 | 6.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.89 | 6.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.75 | 6.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.17 | 5.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.71 | 5.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.04 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.94 | 4.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.97 | 4.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.57 | 4.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.24 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $346.39 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $79.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.23 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 175 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 148 | 47 |
| Losartan Potassium | Losartan Potassium | 136 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 31 |
| Alendronate Sodium | Alendronate Sodium | 83 | 15 |
| Lisinopril | Lisinopril | 71 | 22 |
| Metformin Hcl | Metformin Hcl | 71 | 16 |
| Omeprazole | Omeprazole | 69 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 19 |
| Metformin Hcl Er | Metformin Hcl | 54 | 16 |
| Gabapentin | Gabapentin | 52 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 20 |
| Meloxicam | Meloxicam | 48 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 16 |
| Furosemide | Furosemide | 44 | 11 |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $346.39 · 15 records | Viatris Specialty LLC | ACCRUFER, AREXVY, CAPLYTA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Kerendia, NEXLETOL, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, VOQUEZNA, VRAYLAR, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error